GlassScriptPhysician profile
Nathaniel A Barber
NPI 1093849630
$3,392.06
in general payments reported to CMS, 2019-2025
35 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,031 · 2020: $457 · 2021: $526 · 2022: $560 · 2023: $461 · 2024: $200 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $818.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $817.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $630.70 | 2019-2023 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $357.89 | 2019-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $322.39 | 2022-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $282.69 | 2019-2025 | |
| Abbvie INC. | $252.41 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $243.66 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Astrazeneca Pharmaceuticals LP | $228.36 | 2019-2023 | Farxiga |
| Lilly USA, LLC | $162.80 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Vanda Pharmaceuticals INC. | $116.97 | 2022-2023 | Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $75.00 | 2019 | |
| Pfizer INC. | $62.59 | 2019-2023 | |
| Redhill Biopharma INC. | $62.04 | 2020 | |
| Dynavax Technologies Corporation | $55.38 | 2021-2023 | Heplisav-B |
| Allergan, INC. | $46.56 | 2019-2020 | |
| Seqirus USA INC | $43.49 | 2019-2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $40.46 | 2021 | |
| Boston Scientific Corporation | $39.12 | 2020 | |
| Viiv Healthcare Company | $38.99 | 2024-2025 | Cabenuva |
| Gilead Sciences, INC. | $38.40 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.83 | 2019-2023 | Entyvio |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $30.00 | 2023 | Lifevest |
| Sanofi-Aventis U.S. LLC | $28.84 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.47 | 2022 | |
| Abbott Laboratories | $17.94 | 2021 | |
| Phathom Pharmaceuticals, INC. | $16.15 | 2024 | Voquezna |
| Azurity Pharmaceuticals, INC. | $15.63 | 2025 | Edarbi |
| Ironwood Pharmaceuticals, INC | $15.37 | 2020 | |
| Grifols USA, LLC | $15.00 | 2019 | |
| Janssen Biotech, INC. | $14.94 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.31 | 2019 | |
| Amarin Pharma, INC. | $14.08 | 2019 | |
| Shire North American Group INC | $13.62 | 2019 | |
| Intercept Pharmaceuticals, INC. | $13.33 | 2023 | Ocaliva |
| Medtronic, INC. | $12.23 | 2021 | |
| Genentech USA, INC. | $11.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathaniel Barber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.